Extrawell Pharmaceutical Holdings Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.191 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.191.

Is Extrawell Pharmaceutical Holdings Limited overvalued?

According to Wall Street analysts Extrawell Pharmaceutical Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Extrawell Pharmaceutical Holdings Limited pay dividends?

Extrawell Pharmaceutical Holdings Limited does not currently pay dividends.

What is Extrawell Pharmaceutical Holdings Limited’s EPS estimate?

Extrawell Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Extrawell Pharmaceutical Holdings Limited have?

Extrawell Pharmaceutical Holdings Limited has 2,550,000,000 shares outstanding.

What happened to Extrawell Pharmaceutical Holdings Limited’s price movement after its last earnings report?

Extrawell Pharmaceutical Holdings Limited reported an EPS of -HK$0.191 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Extrawell Pharmaceutical Holdings Limited?

Currently, no hedge funds are holding shares in HK:0858

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Extrawell Pharmaceutical Holdings Limited Stock Smart Score

Outperform

Analyst Consensus

Hold

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

-32.04%

Trailing 12-Months

Asset Growth

18.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Extrawell Pharmaceutical Holdings Limited

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.